{
    "Clinical Trial ID": "NCT02301988",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ipatasertib + Paclitaxel",
        "  Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).",
        "INTERVENTION 2: ",
        "  Placebo + Paclitaxel",
        "  Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Premenopausal or postmenopausal women",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "  Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRI",
        "  Adequate hematologic and organ function within 14 days before the first study treatment",
        "  Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy of breast primary tumor",
        "  For female participants of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatment",
        "Exclusion Criteria:",
        "  Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor (ER)-positive, or progesterone receptor (PgR)-positive breast cancer",
        "  Any prior treatment for the current primary invasive breast cancer",
        "  Participants with cT4 or cN3 stage breast tumors",
        "  Metastatic (Stage IV) breast cancer",
        "  Bilateral invasive breast cancer",
        "  Multicentric breast cancer",
        "  Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants)",
        "  pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.",
        "  Time frame: Surgery visit (at approximately Weeks 14 to 19)",
        "Results 1: ",
        "  Arm/Group Title: Ipatasertib + Paclitaxel",
        "  Arm/Group Description: Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).",
        "  Overall Number of Participants Analyzed: 76",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  17.1        (9.82 to 27.25)",
        "Results 2: ",
        "  Arm/Group Title: Placebo + Paclitaxel",
        "  Arm/Group Description: Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).",
        "  Overall Number of Participants Analyzed: 75",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  13.3        (6.58 to 22.86)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/76 (13.16%)",
        "  Sickle cell anaemia with crisis 1/76 (1.32%)",
        "  Diarrhoea 1/76 (1.32%)",
        "  Pyrexia 1/76 (1.32%)",
        "  Chest pain 1/76 (1.32%)",
        "  Complication associated with device 1/76 (1.32%)",
        "  General physical health deterioration 0/76 (0.00%)",
        "  Device related infection 2/76 (2.63%)",
        "  Pneumonia 1/76 (1.32%)",
        "  Atypical pneumonia 1/76 (1.32%)",
        "  Dehydration 1/76 (1.32%)",
        "Adverse Events 2:",
        "  Total: 3/75 (4.00%)",
        "  Sickle cell anaemia with crisis 0/75 (0.00%)",
        "  Diarrhoea 0/75 (0.00%)",
        "  Pyrexia 1/75 (1.33%)",
        "  Chest pain 0/75 (0.00%)",
        "  Complication associated with device 0/75 (0.00%)",
        "  General physical health deterioration 1/75 (1.33%)",
        "  Device related infection 0/75 (0.00%)",
        "  Pneumonia 1/75 (1.33%)",
        "  Atypical pneumonia 0/75 (0.00%)",
        "  Dehydration 0/75 (0.00%)"
    ]
}